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Fifty-three patients with biochemical relapse (BCR) after receiving external beam radiotherapy (EBRT)
against locally advanced prostate cancer (stage III : International Union Against Cancer [UICC] 6th edition)
between September 1997 and January 2006 at our institution, who were treated with salvage hormonal
therapy (HTx), were followed for a mean period of 75.5 months. There was progression to castration-
resistant prostate cancer (CRPC) during the follow-up period in 17 patients (32.0%). The median time to
CRPC after initial HTx was 17 months. Univariate analysis revealed that time to BCR after EBRT was
significantly associated with progression to CRPC (p＝0.022), while PSA-doubling time just before salvage
HTx was marginally associated with irradiation dose (p＝0.088, p＝0.128 respectively). Multivariate
analysis showed that time to BCR after EBRT was the only significant predictor of progression to CRPC (p＝
0.035, Hazard ratio ; 0.252, 95% confidence interval ; 0.070-0.905) conclusion, time to BCR after EBRT
might be a good predictor for the efficiency of salvage HTx after EBRT against locally advanced prostate
cancer.
(Hinyokika Kiyo 58 : 599-603, 2012)
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緒 言
局所進行性前立腺癌 (stage III) に対する根治的放射
線外照射治療は，近年ホルモン治療を併用するなどの
工夫により，その制癌率は向上しているが，いまだに











prostate cancer ; CRPC) へと進展する症例を経験する．
京大病院では局所進行性前立腺癌 (stage III) に対し
ては，ネオアジュバントホルモン療法と根治的放射線
外照射治療を併用して治療しており，原則として放射










対 象 と 方 法
1997年 9月から2006年 1月までに京大病院で局所進
行性前立腺癌 (stage III) に対し，根治的放射線外照射
治療を行った症例を後ろ向きに解析した．京大病院で
は原則として前立腺癌に対する根治的放射線外照射治
療は ECOG の performance status (PS) が 2以下の症
例に本治療を施行しており，この根治的放射線外照射
治療を行った症例のうち，○1組織学的に腺癌の診断が









治療後の BCR の診断は Phoenix の定義に基づき，
PSA nadir から 2 ng/ml の上昇を BCR と定義した3)．













またはそれ以外），○3 前立腺生検の Gleason score（ 7
以上または未満），○4初診時の PSA 値 (40 ng/ml 以上
または未満），○5 救済ホルモン治療導入時の PSA 値
(6 ng/ml 以上または未満），○6根治的放射線外照射治
療前のホルモン治療の施行期間（ 5カ月超または以
下），○7 根治的放射線外照射治療後から BCR までの
期間（24カ月超または以下），○8 救済ホルモン治療前
の PSA doubling time (PSADT)（ 4カ月以上または未
満），○9 放射線外照射方法（ 3 次元原体照射 three
dimensional-conformal radiotherapy ; 3D-CRT または強









の PSA nadir 値の意義の解釈が難しいと判断し，それ
を解析項目にはいれなかった．
PSADT の算出は Arlen らの報告に従った6)．
Table 1. Patient characteristics of 53 patients with
biochemical relapse after external-beam
radiotherapy who were treated with
salvage hormonal therapy for at least 18
months
Patient characteristics All (n＝53)
Followup period (m) 75.5 (83.7, 39-148)*











Pre-Treatment PSA (ng/ml) 38.4 (60.6, 4.9-430)*
Duration of neoadjuvant hormonal
therapy (m) 5 (5.67, 3-18)*
Modality of radiaiton therapy
3D-CRT 24
IMRT 29
Irradiation dose 72 (73.4, 60-78)*
Time to BCR (m) 26 (29.9, 1-99)*
PSADT before salvage HTx (m) 4.32 (5.58, 1.87-16.9)*
CRPC 17 (17/53＝32.0％)
Time to CPRC (m) 17 (29.1, 2-100)*
Clinical recurrence in patients with
CRPC 12 (12/17＝70.5％)
Time to clinical recurrence (m) 26.5 (41.6, 15-121)*
Cancer death during followup period 3 (3/53＝5.7％)
* median (mean, range). BCR : biochemical relapse, PSADT :
prostate-specific antigen doubling time, PSAV : prostate-specific
antigen velocity, CRPC : castration-resistant prostate cancer,
3D-CRT : three-dimensional-conformal radiotherapy, IMRT :
intensity-modulated radiotherapy, HTx : Hormonal therapy,
EBRT : External beam radiation therapy.
泌尿紀要 58巻 11号 2012年600
PSADT の算出に用いた PSA 値は，救済ホルモン治療
施行前の12カ月以内の値でかつ根治的放射線外照射治
療最終日から 6カ月以降の最初に PSA 上昇を認めた
値とその後のすべての値を用いた．その際，炎症など
による明らかな外れ値は除外した．本算出には






















後から BCR までの期間のみが統計学的に CRPC に進
泌58,11,01-1




済ホルモン治療開始前の PSADT において 4カ月未満
かそれ以上かで差を認め (p＝0.088），根治的放射線





に有意に相関していた (p＝0.035，HR : 0.252，95％
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Table 2. Univariate and multivariate analysis of
significant predictors of responsiveness
against salvage hormonal therapy after






















PSA at the time of salvage HTx
＜6
≧6 0.38
Duration of neoadjuvant HTx (m)
≦5
＞5 0.62
Time to BCR (m)
＞24
≦24 0.022 0.25 0.070-0.905 0.035
PSADT (m)
≧4






≦72 0.12 0.96 0.344-2.721 0.95
PSA : prostate-specific antigen, GS : Gleason score, CI : confi-
dence interval, HTx : hormonal therapy, PSADT : prostate-
specific antigen doubling time, PSAV : prostate-specific antigen
velocity, BCR : biochemical relapse, 3D-CRT : three-dimen-

















































当院で stage III 症例に施行した根治的放射線外照射治






いても少なくとも 1例は CRPC になっていない可能
性がある．しかし，多くの症例で抗アンドロゲン剤交
替療法の効果がなくなった時点を CRPC としている















1) Roberts WB and Han M : Clinical significance and
treatment of biochemical recurrence after definitive
therapy for localized prostate cancer. Surg Oncol
18 : 268-274, 2009
2) Sakamoto M, Mizowaki T, Mitsumori M, et al. : Long-
term outcomes of three-dimensional conformal radia-
tion therapy combined with neoadjuvant hormonal
therapy in Japanese patients with locally advanced
prostate cancer. Int J Clin Oncol 15 : 571-577, 2010
3) Roach M 3rd, Hanks G, Thames H Jr, et al. : Defining
biochemical failure following radiotherapy with or
without hormonal therapy in men with clinically
localized prostate cancer : recommendations of the
RTOG-ASTRO Phoenix Consensus Conference.
Int J Radiat Oncol Biol Phys 65 : 965-974, 2006
4) Mitsumori M, Sasaki Y, Mizowaki T, et al. : Results of
radiation therapy combined with neoadjuvant hormo-
nal therapy for stage III prostate cancer : comparison
of two different definitions of PSA failure. Int J Clin
Oncol 11 : 396-402, 2006
5) Zhu S, Mizowaki T, Nagata Y, et al. : Comparison of
three radiotherapy treatment planning protocols of
definitive external-beam radiation for localized pros-
tate cancer. Int J Clin Oncol 10 : 398-404, 2005
6) Arlen PM, Bianco F, Dahut WL, et al. : Prostate
Specific Antigen Working Group guidelines on pros-
tate specific antigen doubling time. J Urol 179 :
2181-2185, 2008
7) Kakehi Y, Kamoto T, Shiraishi T, et al. : Prospective
evaluation of selection criteria for active surveillance in
Japanese patients with stage T1cN0M0 prostate
cancer. Jpn J Clin Oncol 38 : 122-128, 2008
8) Prostate cancer guideline2007. European Associa-
tion of Urology
9) Rodrigues NA, Chen MH, Catalona WJ, et al. :
Predictors of mortality after androgen-deprivation
therapy in patients with rapidly rising prostate-specific
antigen levels after local therapy for prostate cancer.
Cancer 107 : 515-520, 2006
10) Morote J, Trilla E, Esquena S, et al. : Nadir prostate-
specific antigen best predicts the progression to
androgen-independent prostate cancer. Int J Cancer
108 : 877-881, 2004
11) Denham JW, Steigler A, Wilcox C, et al. : Time to
biochemical failure and prostate-specific antigen dou-
bling time as surrogates for prostate cancer-specific
mortality : evidence from the TROG 96.01 random-
ised controlled trial. Lancet Oncol 9 : 1058-1068,
2008
12) Choueiri TK, Chen MH, D'Amico AV, et al. : Impact
of postoperative prostate-specific antigen disease recur-
rence and the use of salvage therapy on the risk of
death. Cancer 116 : 1887-1892, 2010
13) Morote J, Orsola A, Planas J, et al. : Redefining
clinically significant castration levels in patients with
prostate cancer receiving continuous androgen depri-
vation therapy. J Urol 178 : 1290-1295, 2007
(
Received on February 7, 2012
)Accepted on June 28, 2012
加藤，ほか : 根治的放射線外照射治療・救済ホルモン治療 603
